Unknown aspect of the old disease: does dyslipidemia in systemic AA amyloidosis differ from the dyslipidemia in primary glomerulonephritis?

References

• Virchow VR. Ueber einem Gehirn and Roeckenmark des Menschen auf Gefundene Substanz mit chemischen reaction der Cellulose. Virchows Arch Pathol Anat. 1854;6:135–138
   Google Scholar
• Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses. N Engl J Med. 1980;302(23):1283–1292
   PubMed Web of Science ®Google Scholar
• Dilsen N, Konice M, Aral O, Ocal L. The prevalence, importance and significance of amyloidosis with rheumatic diseases in Turkey. In: Natwig JB, Forre O, Husby G, et al. eds. Amyloidosis. Dordrecht: Kluwer; 1990:870–873
   Google Scholar
• Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol. 1994;8(3):627–634
   PubMed Web of Science ®Google Scholar
• Falk RH, Skinner M. The systemic amyloidoses: An overview. Adv Intern Med. 2000;45:107–137
   PubMedGoogle Scholar
• Cunnane G. Amyloid proteins in pathogenesis of AA amyloidosis. Lancet. 2001;358(9275):4–5
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371
   PubMed Web of Science ®Google Scholar
• Tuglular S, Yalcinkaya F, Paydas S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant. 2002;17(11):2003–2005
   PubMed Web of Science ®Google Scholar
• Appel GB, Radhakrishnan J, D’Agati V. Secondary glomerular disease. In: Brenner BM, ed. The Kidney. Philadelphia, PA: Saunders; 2008:1100–1104
   Google Scholar
• Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003;63(5):1964–1976
   PubMed Web of Science ®Google Scholar
• Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006;17(4 Suppl 2):S145–S147
   PubMed Web of Science ®Google Scholar
• Mallick NP, Short CD. The nephrotic syndrome and ischemic heart disease. Nephron. 1981;27:54–57
   PubMedGoogle Scholar
• Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med. 1985;312(24):1544–1548
   PubMed Web of Science ®Google Scholar
• Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepherd J. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism. 1990;39(2):187–192
   PubMed Web of Science ®Google Scholar
• Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323(9):579–584
   PubMed Web of Science ®Google Scholar
• Hur E, Taskin H, Bozkurt D. Adult native renal biopsy experience of Ege University for 12 consecutive years. BANTAO J. 2010;8(1):22–29
   Google Scholar
• Piskinpasa S, Akoglu H, Koc E, et al. Revisiting secondary amyloidosis for an inadequately investigated feature: Dyslipidemia. Rheumatol Int. 2013;33(4):993–999
   PubMed Web of Science ®Google Scholar
• Ensari C, Ensari A, Tumer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant. 2005;20(8):1721–1725
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol. 2008;19(2):388–395
   PubMed Web of Science ®Google Scholar
• Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF. Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal? Clin Chim Acta. 1981;117(3):317–323
   PubMed Web of Science ®Google Scholar
• Ohta T, Matsuda I. Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta. 1981;117(2):133–143
   PubMed Web of Science ®Google Scholar
• Michaeli J, Bar-On H, Shafrir E. Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome. Isr J Med Sci. 1981;17(11):1001–1008
   PubMedGoogle Scholar
• Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003;63(5):1756–1763
   PubMed Web of Science ®Google Scholar
• Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ. 1996;312(7038):1061–1065
   PubMed Web of Science ®Google Scholar
• Kazumi T, Kawaguchi A, Hirano T, Yoshino G. C-reactive protein in young, apparently healthy men: Associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism. 2003;52(9):1113–1116
   PubMed Web of Science ®Google Scholar
• Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999;31(5):619–631
   PubMedGoogle Scholar
• Cengiz K, Bakan A, Yilmaz H. Lipoprotein abnormalities in patients with secondary renal amyloidosis. Int Urol Nephrol. 2001;32(4):615–619
   PubMedGoogle Scholar